SAVITRI KRISHNAMURTHY, M.D.
Medical Practice at Holcombe Blvd, Houston, TX
License number
Texas 153690
Category
Medical Practice
Type
Anatomic Pathology
License number
Texas K8268
Category
Medical Practice
Type
Anatomic Pathology & Clinical Pathology
Address
Address
1515 Holcombe Blvd, Houston, TX 77030
Phone
(713) 792-6161
(713) 792-2991
(713) 792-2991
Personal information
See more information about SAVITRI KRISHNAMURTHY at radaris.comName
Address
Phone
2001 Holcombe Blvd, Houston, TX 77030
6540 Bellows Ln, Houston, TX 77030
Professional information
See more information about SAVITRI KRISHNAMURTHY at trustoria.com
Professor At Md Anderson Cancer Center
Professor At Md Anderson Cancer Center
Position:
Professor at MD Anderson Cancer Center
Location:
Houston, Texas Area
Industry:
Hospital & Health Care
Work:
MD Anderson Cancer Center
-
Professor
Savitri Krishnamurthy, Houston TX
Savitri Krishnamurthy, Houston TX
Specialties:
Anatomic Pathology & Clinical Pathology, Cytopathology, Anatomic Pathology
Work:
Univ. of Texas M.D. Anderson C.
1515 Holcombe Blvd, Houston, TX 77030
1515 Holcombe Blvd, Houston, TX 77030
Education:
Calcutta Medical College (1986)
Savitri Krishnamurthy, Houston TX
Savitri Krishnamurthy, Houston TX
Specialties:
Pathologist
Address:
1515 Holcombe Blvd, Houston, TX 77030
Education:
Doctor of Medicine
Board certifications:
American Board of Pathology Certification in Clinical Pathology (Pathology), American Board of Pathology Sub-certificate in Cytopathology (Pathology)
Cancer Immunotherapy Incorporating P53
Cancer Immunotherapy Incorporating P53
US Patent:
2006015, Jul 13, 2006
Filed:
Nov 17, 2005
Appl. No.:
11/281922
Inventors:
Massimo Cristofanilli - Pearland TX, US
Savitri Krishnamurthy - Houston TX, US
Kerstin Menander - Bellaire TX, US
Gabriel Hortobagyi - Bellaire TX, US
Savitri Krishnamurthy - Houston TX, US
Kerstin Menander - Bellaire TX, US
Gabriel Hortobagyi - Bellaire TX, US
International Classification:
A61K 48/00
US Classification:
424093200
Abstract:
A method of stimulating an immune response to a tumor in an immunocompetent subject by administering a p53 expression construct to a tumor. The construct expresses p53 in tumor cells in an amount sufficient to stimulate an immune response against the tumor. Both viral and non-viral delivery systems are contemplated. The method can be combined with chemotherapy agents as well as with other cancer therapies.